GW501516

From WikiMD's WELLNESSPEDIA

Chemical structure of GW501516

GW501516, also known as GW1516, GSK-516, and Endurobol, is a peroxisome proliferator-activated receptor delta (PPAR_) agonist that was initially developed in the 1990s as a potential treatment for metabolic diseases and cardiovascular diseases. It is known for its ability to enhance endurance and fat burning in animal studies, which has led to its use as a performance-enhancing drug in sports.

Mechanism of Action[edit]

GW501516 works by activating the PPAR_ receptor, which is a type of nuclear receptor that regulates the expression of genes involved in energy metabolism. When activated, PPAR_ increases the oxidation of fatty acids in muscle tissue, leading to improved endurance and reduced fat mass. This makes it an attractive compound for athletes looking to enhance their performance.

Development and Research[edit]

GW501516 was developed by GlaxoSmithKline in collaboration with Ligand Pharmaceuticals. Initial studies showed promising results in improving lipid profiles and increasing high-density lipoprotein (HDL) levels, which are beneficial for cardiovascular health. However, further research revealed that long-term use of GW501516 in animal models led to the development of cancer in several organs, which halted its development for therapeutic use.

Use in Sports[edit]

Despite its potential risks, GW501516 has been used by athletes as a performance-enhancing drug. It is banned by the World Anti-Doping Agency (WADA) and is classified as a prohibited substance under the category of hormone and metabolic modulators. Athletes caught using GW501516 face penalties, including suspension from competition.

Safety and Side Effects[edit]

The use of GW501516 is associated with significant health risks, primarily due to its potential to cause cancer. Other side effects may include liver damage, gastrointestinal issues, and muscle pain. Due to these risks, it is not approved for human use by any regulatory agency.

Related Pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=GW501516&oldid=6626562"